Mammalian SWI/SNF chromatin remodeling complexes: emerging mechanisms and therapeutic strategies
RC Centore, GJ Sandoval, LMM Soares, C Kadoch… - Trends in Genetics, 2020 - cell.com
Small molecule-based targeting of chromatin regulatory factors has emerged as a promising
therapeutic strategy in recent years. The development and ongoing clinical evaluation of …
therapeutic strategy in recent years. The development and ongoing clinical evaluation of …
Molecular events in neuroendocrine prostate cancer development
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. NEPC arises
de novo only rarely; the disease predominantly develops from adenocarcinoma in response …
de novo only rarely; the disease predominantly develops from adenocarcinoma in response …
[HTML][HTML] Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer
Acquired resistance to tyrosine kinase inhibitors (TKI), such as osimertinib used to treat
EGFR-mutant lung adenocarcinomas, limits long-term efficacy and is frequently caused by …
EGFR-mutant lung adenocarcinomas, limits long-term efficacy and is frequently caused by …
Chromatin remodellers as therapeutic targets
HA Malone, CWM Roberts - Nature Reviews Drug Discovery, 2024 - nature.com
Large-scale cancer genome sequencing studies have revealed that chromatin regulators
are frequently mutated in cancer. In particular, more than 20% of cancers harbour mutations …
are frequently mutated in cancer. In particular, more than 20% of cancers harbour mutations …
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for
targeted protein degradation. A bifunctional PROTAC molecule consists of a ligand (mostly …
targeted protein degradation. A bifunctional PROTAC molecule consists of a ligand (mostly …
Vulnerabilities of mutant SWI/SNF complexes in cancer
KC Helming, X Wang, CWM Roberts - Cancer cell, 2014 - cell.com
Cancer genome sequencing efforts have revealed the novel theme that chromatin modifiers
are frequently mutated across a wide spectrum of cancers. Mutations in genes encoding …
are frequently mutated across a wide spectrum of cancers. Mutations in genes encoding …
SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities
A Andrades, P Peinado, JC Alvarez-Perez… - Molecular cancer, 2023 - Springer
Hematological malignancies are a highly heterogeneous group of diseases with varied
molecular and phenotypical characteristics. SWI/SNF (SWItch/Sucrose Non-Fermentable) …
molecular and phenotypical characteristics. SWI/SNF (SWItch/Sucrose Non-Fermentable) …
Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer
L Duplaquet, K So, AW Ying, SP Choudhuri, X Li… - Cancer Cell, 2024 - cell.com
Small cell lung cancers (SCLCs) are composed of heterogeneous subtypes marked by
lineage-specific transcription factors, including ASCL1, NEUROD1, and POU2F3. POU2F3 …
lineage-specific transcription factors, including ASCL1, NEUROD1, and POU2F3. POU2F3 …
A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia
Cancers that appear pathologically similar often respond differently to the same drug
regimens. Methods to better match patients to drugs are in high demand. We demonstrate a …
regimens. Methods to better match patients to drugs are in high demand. We demonstrate a …
The SMARCA2/4 ATPase domain surpasses the bromodomain as a drug target in SWI/SNF-mutant cancers: insights from cDNA rescue and PFI-3 inhibitor studies
B Vangamudi, TA Paul, PK Shah, M Kost-Alimova… - Cancer research, 2015 - AACR
The SWI/SNF multisubunit complex modulates chromatin structure through the activity of two
mutually exclusive catalytic subunits, SMARCA2 and SMARCA4, which both contain a …
mutually exclusive catalytic subunits, SMARCA2 and SMARCA4, which both contain a …